{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T19:13:06Z","timestamp":1793387586071,"version":"4.5.0"},"reference-count":113,"publisher":"Open Exploration Publishing","license":[{"start":{"date-parts":[[2025,5,7]],"date-time":"2025-05-07T00:00:00Z","timestamp":1746576000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Explor Med"],"accepted":{"date-parts":[[2025,4,21]]},"abstract":"<jats:p xml:lang=\"en\">Vaccines are typically designed either for human or veterinary use. Using One Health principles it would be more efficient to develop a single vaccine to cover all animal and human species at threat from a specific pathogen. A major issue for designing One Health vaccines is that some commonly used human adjuvants such as aluminium salts are not suitable for some animal species, such as felines, where they can cause injection site sarcomas. Conversely, some commonly used animal adjuvants such as mineral oil emulsions are too reactogenic to be used in humans. In addition, species-specific differences in innate immune receptors such as Toll-like receptors (TLR) may mean an adjuvant that works in one species does not work in another. This review presents an overview of human and veterinary adjuvants in use and from this list identifies those that might be most suitable for use in a One Health vaccine strategy. Two notable adjuvant candidates already supported by both human and animal data are squalene oil emulsions and delta inulin-CpG combination adjuvant known as Advax-CpG55.2. These two adjuvants have already been shown to be safe and effective across multiple species including when formulated in influenza vaccines. This could be highly relevant to adjuvant selection for vaccines in development against the current North American bovine H5N1 avian influenza outbreak with the potential need to cover multiple susceptible species including birds, cattle and cats in addition to humans. Additional considerations for One Health adjuvants would be suitable administration routes and dosing across species of widely varying size, physiology and genetics. The availability of adjuvants such as squalene emulsions and Advax-CpG55.2 with broad species activity and safety, including in humans, should make One Health vaccine approaches more common in the future.<\/jats:p>","DOI":"10.37349\/emed.2025.1001316","type":"journal-article","created":{"date-parts":[[2025,5,7]],"date-time":"2025-05-07T07:51:32Z","timestamp":1746604292000},"update-policy":"https:\/\/doi.org\/10.37349\/open_exploration_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["One Health adjuvant selection for vaccines against zoonotic infections"],"prefix":"10.37349","volume":"6","author":[{"given":"Anna","family":"Antipov","sequence":"first","affiliation":[{"name":"Vaxine Pty Ltd, Warradale, Adelaide, South Australia 5046, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1580-5245","authenticated-orcid":false,"given":"Nikolai","family":"Petrovsky","sequence":"additional","affiliation":[{"name":"Vaxine Pty Ltd, Warradale, Adelaide, South Australia 5046, Australia; Australian Respiratory and Sleep Medicine Institute, Adelaide, South Australia 5042, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"21850","published-online":{"date-parts":[[2025,5,7]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1010537","article-title":"One Health: A new definition for a sustainable and healthy future","volume":"18","author":"Adisasmito","year":"2022","journal-title":"PLoS Pathog"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.3390\/tropicalmed4020088","article-title":"The One Health Approach-Why Is It So Important?","volume":"4","author":"Mackenzie","year":"2019","journal-title":"Trop Med Infect Dis"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"971","DOI":"10.4161\/hv.20202","article-title":"New vaccines needed for pathogens infecting animals and humans: One Health","volume":"8","author":"Guti\u00e9rrez","year":"2012","journal-title":"Hum Vaccin Immunother"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1038\/nature06536","article-title":"Global trends in emerging infectious diseases","volume":"451","author":"Jones","year":"2008","journal-title":"Nature"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1126\/science.1118391","article-title":"Bats are natural reservoirs of SARS-like coronaviruses","volume":"310","author":"Li","year":"2005","journal-title":"Science"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.3390\/microorganisms8091405","article-title":"Zoonotic Diseases: Etiology, Impact, and Control","volume":"8","author":"Rahman","year":"2020","journal-title":"Microorganisms"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.3390\/v10020093","article-title":"MERS-CoV: Understanding the Latest Human Coronavirus Threat","volume":"10","author":"Chafekar","year":"2018","journal-title":"Viruses"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-020-0147-3","article-title":"Ebola virus disease","volume":"6","author":"Jacob","year":"2020","journal-title":"Nat Rev Dis Primers"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1080\/22221751.2022.2155072","article-title":"Alarming situation of emerging H5 and H7 avian influenza and effective control strategies","volume":"12","author":"Shi","year":"2023","journal-title":"Emerg Microbes Infect"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"875","DOI":"10.56499\/jppres22.1430_10.5.875","article-title":"Technology surveillance in veterinary vaccine adjuvants (2015-2022): University-industry interaction","volume":"10","author":"Dom\u00ednguez-Odio","year":"2022","journal-title":"J Pharm Pharmacogn Res"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"2637","DOI":"10.1098\/rstb.2009.0133","article-title":"Livestock infectious diseases and zoonoses","volume":"364","author":"Tomley","year":"2009","journal-title":"Philos Trans R Soc Lond B Biol Sci"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"539","DOI":"10.20506\/rst.33.2.2289","article-title":"Animal and human influenzas","volume":"33","author":"Peiris","year":"2014","journal-title":"Rev Sci Tech"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"61","DOI":"10.14202\/vetworld.2015.61-65","article-title":"Japanese encephalitis: Challenges and intervention opportunities in Nepal","volume":"8","author":"Ghimire","year":"2015","journal-title":"Vet World"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/B978-0-323-04579-7.00004-6","article-title":"Emerging and re-emerging pathogens and diseases","author":"Levitt","year":"2010","journal-title":"Infectious Diseases"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1586\/14760584.2013.811198","article-title":"Vaccine adjuvant safety: the elephant in the room","volume":"12","author":"Petrovsky","year":"2013","journal-title":"Expert Rev Vaccines"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"456","DOI":"10.2376\/0005-9366-128-456","article-title":"Adjuvants for veterinary vaccines--types and modes of action","volume":"128","author":"Gerdts","year":"2015","journal-title":"Berl Munch Tierarztl Wochenschr"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines10050819","article-title":"An Overview of Vaccine Adjuvants: Current Evidence and Future Perspectives","volume":"10","author":"Facciol\u00e0","year":"2022","journal-title":"Vaccines (Basel)"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1007\/s00705-010-0863-1","article-title":"Adjuvants and delivery systems in veterinary vaccinology: current state and future developments","volume":"156","author":"Heegaard","year":"2011","journal-title":"Arch Virol"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1007\/s40264-015-0350-4","article-title":"Comparative Safety of Vaccine Adjuvants: A Summary of Current Evidence and Future Needs","volume":"38","author":"Petrovsky","year":"2015","journal-title":"Drug Saf"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines11020453","article-title":"Immunogenicity of Different Types of Adjuvants and Nano-Adjuvants in Veterinary Vaccines: A Comprehensive Review","volume":"11","author":"Nooraei","year":"2023","journal-title":"Vaccines (Basel)"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.3389\/fvets.2023.1307585","article-title":"Commercial vaccines used in poultry, cattle, and aquaculture: a multidirectional comparison","volume":"10","author":"Dom\u00ednguez-Odio","year":"2024","journal-title":"Front Vet Sci"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1098\/rspb.2013.2839","article-title":"Veterinary and human vaccine evaluation methods","volume":"281","author":"Knight-Jones","year":"2014","journal-title":"Proc Biol Sci"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-023-01557-7","article-title":"Vaccine adjuvants: mechanisms and platforms","volume":"8","author":"Zhao","year":"2023","journal-title":"Signal Transduct Target Ther"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/j.jsps.2011.06.003","article-title":"Vaccine adjuvants - Current status and prospects on controlled release adjuvancity","volume":"19","author":"Sivakumar","year":"2011","journal-title":"Saudi Pharm J"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1002\/btm2.10663","article-title":"Vaccine adjuvants for infectious disease in the clinic","volume":"9","author":"Goetz","year":"2024","journal-title":"Bioeng Transl Med"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"5670","DOI":"10.1016\/j.vaccine.2019.07.098","article-title":"Adjuvant Systems for vaccines: 13\u202fyears of post-licensure experience in diverse populations have progressed the way adjuvanted vaccine safety is investigated and understood","volume":"37","author":"Laup\u00e8ze","year":"2019","journal-title":"Vaccine"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1089\/vim.2017.0049","article-title":"Adjuvants for Animal Vaccines","volume":"31","author":"Burakova","year":"2018","journal-title":"Viral Immunol"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.1128\/cdli.9.6.1260-1269.2002","article-title":"Immunomodulatory effects of CpG oligodeoxynucleotides on established th2 responses","volume":"9","author":"Kitagaki","year":"2002","journal-title":"Clin Diagn Lab Immunol"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"3942","DOI":"10.4049\/jimmunol.162.7.3942","article-title":"Adjuvant-guided type-1 and type-2 immunity: infectious\/noninfectious dichotomy defines the class of response","volume":"162","author":"Yip","year":"1999","journal-title":"J Immunol"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-15096-z","article-title":"Influence of hydrocarbon oil structure on adjuvanticity and autoimmunity","volume":"7","author":"Yau","year":"2017","journal-title":"Sci Rep"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines9030222","article-title":"Natural and Synthetic Saponins as Vaccine Adjuvants","volume":"9","author":"Wang","year":"2021","journal-title":"Vaccines (Basel)"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"6659","DOI":"10.1016\/j.vaccine.2020.08.054","article-title":"Adjuvants for swine vaccines: Mechanisms of actions and adjuvant effects","volume":"38","author":"Charerntantanakul","year":"2020","journal-title":"Vaccine"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1186\/s13567-023-01151-3","article-title":"An inventory of adjuvants used for vaccination in horses: the past, the present and the future","volume":"54","author":"Carnet","year":"2023","journal-title":"Vet Res"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1111\/j.0818-9641.2004.01272.x","article-title":"Vaccine adjuvants: current state and future trends","volume":"82","author":"Petrovsky","year":"2004","journal-title":"Immunol Cell Biol"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1043109","article-title":"New-age vaccine adjuvants, their development, and future perspective","volume":"14","author":"Verma","year":"2023","journal-title":"Front Immunol"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1016\/j.cbpa.2022.102172","article-title":"Toll-like receptor (TLR) agonists as a driving force behind next-generation vaccine adjuvants and cancer therapeutics","volume":"70","author":"Kaur","year":"2022","journal-title":"Curr Opin Chem Biol"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1080\/21645515.2014.1004026","article-title":"Advances in aluminum hydroxide-based adjuvant research and its mechanism","volume":"11","author":"He","year":"2015","journal-title":"Hum Vaccin Immunother"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1038\/s41573-021-00163-y","article-title":"Emerging concepts in the science of vaccine adjuvants","volume":"20","author":"Pulendran","year":"2021","journal-title":"Nat Rev Drug Discov"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1016\/s0020-7519(03)00053-5","article-title":"Recent advances in veterinary vaccine adjuvants","volume":"33","author":"Singh","year":"2003","journal-title":"Int J Parasitol"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1016\/j.smim.2020.101426","article-title":"The continued advance of vaccine adjuvants - \u2018we can work it out\u2019","volume":"50","author":"O\u2019Hagan","year":"2020","journal-title":"Semin Immunol"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.smim.2018.08.001","article-title":"Systems analysis of human vaccine adjuvants","volume":"39","author":"Harandi","year":"2018","journal-title":"Semin Immunol"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2024.2363016","article-title":"Clinical development of SpikoGen\u00ae, an Advax-CpG55.2 adjuvanted recombinant spike protein vaccine","volume":"20","author":"Petrovsky","year":"2024","journal-title":"Hum Vaccin Immunother"},{"key":"ref43","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.smim.2018.05.001","article-title":"Correlates of adjuvanticity: A review on adjuvants in licensed vaccines","volume":"39","author":"Del","year":"2018","journal-title":"Semin Immunol"},{"key":"ref44","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1080\/21645515.2016.1225635","article-title":"From discovery to licensure, the Adjuvant System story","volume":"13","author":"Gar\u00e7on","year":"2017","journal-title":"Hum Vaccin Immunother"},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-27096-9","article-title":"Adaptation, spread and transmission of SARS-CoV-2 in farmed minks and associated humans in the Netherlands","volume":"12","author":"Lu","year":"2021","journal-title":"Nat Commun"},{"key":"ref46","doi-asserted-by":"publisher","DOI":"10.2807\/1560-7917.ES.2023.28.28.2200741","article-title":"SARS-CoV-2 in lions, gorillas and zookeepers in the Rotterdam Zoo, the Netherlands, a One Health investigation, November 2021","volume":"28","author":"Dusseldorp","year":"2023","journal-title":"Euro Surveill"},{"key":"ref47","doi-asserted-by":"publisher","first-page":"658","DOI":"10.3201\/eid2903.220915","article-title":"SARS-CoV-2 Infection in a Hippopotamus, Hanoi, Vietnam","volume":"29","author":"Bui","year":"2023","journal-title":"Emerg Infect Dis"},{"key":"ref48","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/j.chom.2025.01.010","article-title":"A brief history of human infections with H5Ny avian influenza viruses","volume":"33","author":"Wang","year":"2025","journal-title":"Cell Host Microbe"},{"key":"ref49","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1099\/jmm.0.038943-0","article-title":"Alum adjuvant: some of the tricks of the oldest adjuvant","volume":"61","author":"Kool","year":"2012","journal-title":"J Med Microbiol"},{"key":"ref50","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1177\/0300985818809142","article-title":"Granulomas Following Subcutaneous Injection With Aluminum Adjuvant-Containing Products in Sheep","volume":"56","author":"As\u00edn","year":"2019","journal-title":"Vet Pathol"},{"key":"ref51","doi-asserted-by":"publisher","first-page":"E130","DOI":"10.1111\/vco.12358","article-title":"Feline vaccine-associated sarcomagenesis: Is there an inflammation-independent role for aluminium?","volume":"16","author":"AbdelMageed","year":"2018","journal-title":"Vet Comp Oncol"},{"key":"ref52","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1111\/j.1939-1676.2003.tb02448.x","article-title":"Adjuvants in veterinary vaccines: modes of action and adverse effects","volume":"17","author":"Spickler","year":"2003","journal-title":"J Vet Intern Med"},{"key":"ref53","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jcpa.2018.06.008","article-title":"Feline Injection Site Sarcomas: Data from Switzerland 2009-2014","volume":"163","author":"Graf","year":"2018","journal-title":"J Comp Pathol"},{"key":"ref54","doi-asserted-by":"publisher","first-page":"1527","DOI":"10.20506\/rst.15.4.985","article-title":"Control of avian mycoplasmoses by vaccination","volume":"15","author":"Whithear","year":"1996","journal-title":"Rev Sci Tech"},{"key":"ref55","doi-asserted-by":"publisher","first-page":"1740","DOI":"10.1016\/j.fsi.2013.02.029","article-title":"Adjuvants and immunostimulants in fish vaccines: current knowledge and future perspectives","volume":"35","author":"Tafalla","year":"2013","journal-title":"Fish Shellfish Immunol"},{"key":"ref56","doi-asserted-by":"publisher","first-page":"2666","DOI":"10.1016\/s0264-410x(00)00498-9","article-title":"Adjuvants designed for veterinary and human vaccines","volume":"19","author":"Aucouturier","year":"2001","journal-title":"Vaccine"},{"key":"ref57","first-page":"397","article-title":"Carcinogenic effects of polycyclic hydrocarbon carcinogen administration to mice during pregnancy on the progeny","volume":"46","author":"Bulay","year":"1971","journal-title":"J Natl Cancer Inst"},{"key":"ref58","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1080\/1059924X.2011.534045","article-title":"Unintentional needlestick injuries in livestock production: a case series and review","volume":"16","author":"Jennissen","year":"2011","journal-title":"J Agromedicine"},{"key":"ref59","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1631\/jzus.2007.B0153","article-title":"Adjuvant effects of saponins on animal immune responses","volume":"8","author":"Rajput","year":"2007","journal-title":"J Zhejiang Univ Sci B"},{"key":"ref60","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1016\/j.addr.2004.02.004","article-title":"Current status and potential application of ISCOMs in veterinary medicine","volume":"56","author":"Morein","year":"2004","journal-title":"Adv Drug Deliv Rev"},{"key":"ref61","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1111\/J.1095-8649.1987.TB05313.X","article-title":"Effects of immunopotentiating agents on the immune response of rainbow trout, Salmo gair dneri Richardson, to ERM vaccine","volume":"31","author":"Grayson","year":"1987","journal-title":"J Fish Biol"},{"key":"ref62","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/s0165-2427(02)00246-5","article-title":"Biological activity of immunostimulatory CpG DNA motifs in domestic animals","volume":"91","author":"Mutwiri","year":"2003","journal-title":"Vet Immunol Immunopathol"},{"key":"ref63","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.vetimm.2003.10.001","article-title":"In vivo immunostimulatory effects of CpG oligodeoxynucleotide in cattle and sheep","volume":"98","author":"Nichani","year":"2004","journal-title":"Vet Immunol Immunopathol"},{"key":"ref64","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-83026-x","article-title":"Enhancing antibody levels and T cell activity of quadrivalent influenza vaccine by combining it with CpG HP021","volume":"14","author":"Ji","year":"2024","journal-title":"Sci Rep"},{"key":"ref65","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1111\/jvp.13429","article-title":"Safety and immunogenicity of an adjuvanted recombinant spike protein-based severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine, SpikeVet\u2122, in selected Carnivora, Primates and Artiodactyla in Australian zoos","volume":"47","author":"McLelland","year":"2024","journal-title":"J Vet Pharmacol Ther"},{"key":"ref66","doi-asserted-by":"publisher","first-page":"3224","DOI":"10.1016\/j.vaccine.2023.04.028","article-title":"Long-term immunogenicity and safety of the hepatitis B vaccine HepB-CpG (HEPLISAV-B) compared with HepB-Eng (Engerix-B) in adults with chronic kidney disease","volume":"41","author":"Girndt","year":"2023","journal-title":"Vaccine"},{"key":"ref67","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2024.2429231","article-title":"Safety and immunogenicity of a SARS-CoV-2 recombinant protein subunit vaccine adjuvanted with Alum + CpG 1018 in healthy Indonesian adults: A multicenter, randomized, comparative, observer-blind, placebo-controlled phase 2 study","volume":"20","author":"Maddeppungeng","year":"2024","journal-title":"Hum Vaccin Immunother"},{"key":"ref68","doi-asserted-by":"publisher","first-page":"5920","DOI":"10.1016\/j.vaccine.2015.09.030","article-title":"Advax\u2122, a novel microcrystalline polysaccharide particle engineered from delta inulin, provides robust adjuvant potency together with tolerability and safety","volume":"33","author":"Petrovsky","year":"2015","journal-title":"Vaccine"},{"key":"ref69","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1111\/imcb.12774","article-title":"Dendritic cell-specific intercellular adhesion molecule-3-grabbing nonintegrin (DC-SIGN) is a cellular receptor for delta inulin adjuvant","volume":"102","author":"Stewart","year":"2024","journal-title":"Immunol Cell Biol"},{"key":"ref70","doi-asserted-by":"publisher","first-page":"1999","DOI":"10.1016\/j.vaccine.2012.12.077","article-title":"A novel hepatitis B vaccine containing Advax\u2122, a polysaccharide adjuvant derived from delta inulin, induces robust humoral and cellular immunity with minimal reactogenicity in preclinical testing","volume":"31","author":"Saade","year":"2013","journal-title":"Vaccine"},{"key":"ref71","doi-asserted-by":"publisher","first-page":"3182","DOI":"10.1016\/j.vaccine.2022.04.041","article-title":"Covax-19\/Spikogen\u00ae vaccine based on recombinant spike protein extracellular domain with Advax-CpG55.2 adjuvant provides single dose protection against SARS-CoV-2 infection in hamsters","volume":"40","author":"Li","year":"2022","journal-title":"Vaccine"},{"key":"ref72","doi-asserted-by":"publisher","first-page":"5940","DOI":"10.1016\/j.vaccine.2021.07.087","article-title":"Immunisation of ferrets and mice with recombinant SARS-CoV-2 spike protein formulated with Advax-SM adjuvant protects against COVID-19 infection","volume":"39","author":"Li","year":"2021","journal-title":"Vaccine"},{"key":"ref73","doi-asserted-by":"publisher","first-page":"4625","DOI":"10.1016\/j.vaccine.2022.06.043","article-title":"A typhoid fever protein capsular matrix vaccine candidate formulated with Advax-CpG adjuvant induces a robust and durable anti-typhoid Vi polysaccharide antibody response in mice, rabbits and nonhuman primates","volume":"40","author":"Honda-Okubo","year":"2022","journal-title":"Vaccine"},{"key":"ref74","doi-asserted-by":"publisher","first-page":"101","DOI":"10.12834\/VetIt.396.1876.2","article-title":"Preliminary results on innocuity and immunogenicity of an inactivated vaccine against Peste des petits ruminants","volume":"52","author":"Ronchi","year":"2016","journal-title":"Vet Ital"},{"key":"ref75","doi-asserted-by":"publisher","first-page":"7446","DOI":"10.1016\/j.vaccine.2021.10.075","article-title":"Novel adjuvants enhance immune responses elicited by a replication-defective human cytomegalovirus vaccine in nonhuman primates","volume":"39","author":"Li","year":"2021","journal-title":"Vaccine"},{"key":"ref76","doi-asserted-by":"publisher","DOI":"10.1186\/s13567-014-0130-7","article-title":"Safety and immunogenicity of a delta inulin-adjuvanted inactivated Japanese encephalitis virus vaccine in pregnant mares and foals","volume":"45","author":"Bielefeldt-Ohmann","year":"2014","journal-title":"Vet Res"},{"key":"ref77","doi-asserted-by":"publisher","DOI":"10.3390\/v11030212","article-title":"Efficacy of an Adjuvanted Middle East Respiratory Syndrome Coronavirus Spike Protein Vaccine in Dromedary Camels and Alpacas","volume":"11","author":"Adney","year":"2019","journal-title":"Viruses"},{"key":"ref78","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines12010041","article-title":"Intranasally Delivered Adenoviral Vector Protects Chickens against Newcastle Disease Virus: Vaccine Manufacturing and Stability Assessments for Liquid and Lyophilized Formulations","volume":"12","author":"Farn\u00f3s","year":"2023","journal-title":"Vaccines (Basel)"},{"key":"ref79","unstructured":"Administration of Vaccines in Animals. [Cited 2025 Apr 26]. Available from: https:\/\/www.msdvetmanual.com\/pharmacology\/vaccines-and-immunotherapy\/administration-of-vaccines-in-animals"},{"key":"ref80","doi-asserted-by":"publisher","unstructured":"Tizard IR. Adjuvants and adjuvanticity. In: Vaccines for Veterinarians. Elsevier; 2021. pp. 75\u201386.e1.","DOI":"10.1016\/B978-0-323-68299-2.00016-2"},{"key":"ref81","doi-asserted-by":"publisher","first-page":"258","DOI":"10.4103\/0975-7406.103231","article-title":"Formulation and delivery of vaccines: Ongoing challenges for animal management","volume":"4","author":"Sharma","year":"2012","journal-title":"J Pharm Bioallied Sci"},{"key":"ref82","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines11101585","article-title":"Next Generation Mucosal Vaccine Strategy for Respiratory Pathogens","volume":"11","author":"Dotiwala","year":"2023","journal-title":"Vaccines (Basel)"},{"key":"ref83","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1093\/ilar\/ilv009","article-title":"Large animal models for vaccine development and testing","volume":"56","author":"Gerdts","year":"2015","journal-title":"ILAR J"},{"key":"ref84","doi-asserted-by":"publisher","first-page":"246","DOI":"10.4161\/hv.4.3.5318","article-title":"Novel vaccines and adjuvant systems: the utility of animal models for predicting immunogenicity in humans","volume":"4","author":"Davis","year":"2008","journal-title":"Hum Vaccin"},{"key":"ref85","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/s0165-2427(98)00089-0","article-title":"Cytokine adjuvants: lessons from the past--guidelines for the future?","volume":"63","author":"Hughes","year":"1998","journal-title":"Vet Immunol Immunopathol"},{"key":"ref86","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.jtbi.2019.01.017","article-title":"Dose finding for new vaccines: The role for immunostimulation\/immunodynamic modelling","volume":"465","author":"Rhodes","year":"2019","journal-title":"J Theor Biol"},{"key":"ref87","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1007\/s12026-016-8819-5","article-title":"Adjuvants- and vaccines-induced autoimmunity: animal models","volume":"65","author":"Ruiz","year":"2017","journal-title":"Immunol Res"},{"key":"ref88","doi-asserted-by":"crossref","unstructured":"Wilson WD, Pusterla N, Long MT. Immunoprophylaxis. 2nd edition. 2014. pp. 551\u201370.","DOI":"10.1016\/B978-1-4557-0891-8.00064-6"},{"key":"ref89","unstructured":"Vaccination of Exotic Mammals. [Cited 2025 Apr 26]. Available from: https:\/\/www.msdvetmanual.com\/exotic-and-laboratory-animals\/vaccination-of-exotic-mammals\/vaccination-of-exotic-mammals"},{"key":"ref90","first-page":"352","article-title":"Use of Vaccines in Exotic Animals","volume":"24","author":"Bittle","year":"1993","journal-title":"J Zoo Wildl Med"},{"key":"ref91","doi-asserted-by":"publisher","first-page":"4118","DOI":"10.1039\/d3tb02861e","article-title":"Vaccine adjuvants: current status, research and development, licensing, and future opportunities","volume":"12","author":"Cui","year":"2024","journal-title":"J Mater Chem B"},{"key":"ref92","doi-asserted-by":"publisher","first-page":"2968","DOI":"10.1016\/j.vaccine.2023.03.048","article-title":"Prenatal tetanus-diphtheria-acellular pertussis vaccine effectiveness at preventing infant pertussis","volume":"41","author":"Vargas-Zambrano","year":"2023","journal-title":"Vaccine"},{"key":"ref93","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1016\/S1473-3099(24)00588-7","article-title":"Serotype distribution of remaining invasive pneumococcal disease after extensive use of ten-valent and 13-valent pneumococcal conjugate vaccines (the PSERENADE project): a global surveillance analysis","volume":"25","author":"Garcia","year":"2025","journal-title":"Lancet Infect Dis"},{"key":"ref94","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.15585\/mmwr.mm7349a3","article-title":"New Dosing Interval and Schedule for the Bexsero MenB-4C Vaccine: Updated Recommendations of the Advisory Committee on Immunization Practices - United States, October 2024","volume":"73","author":"Schillie","year":"2024","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"ref95","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1177\/10915818211031239","article-title":"Evaluation of the AV7909 Anthrax Vaccine Toxicity in Sprague Dawley Rats Following Three Intramuscular Administrations","volume":"40","author":"Rao","year":"2021","journal-title":"Int J Toxicol"},{"key":"ref96","first-page":"1","article-title":"The safety and immunogenicity of a recombinant hepatitis B vaccine in neonates","volume":"102","author":"Gunn","year":"1989","journal-title":"N Z Med J"},{"key":"ref97","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics15071884","article-title":"Aluminum Adjuvants-\u2018Back to the Future\u2019","volume":"15","author":"Laera","year":"2023","journal-title":"Pharmaceutics"},{"key":"ref98","doi-asserted-by":"publisher","DOI":"10.3390\/v16010054","article-title":"Japanese Encephalitis: Risk of Emergence in the United States and the Resulting Impact","volume":"16","author":"Monath","year":"2023","journal-title":"Viruses"},{"key":"ref99","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-024-10379-z","article-title":"A population-based study on the burden of hospitalized pediatric pneumococcal disease in Taiwan before and after the introduction of 13-valent pneumococcal conjugate vaccine into the childhood immunization program in 2015","volume":"25","author":"Yen","year":"2025","journal-title":"BMC Infect Dis"},{"key":"ref100","first-page":"656","article-title":"Boostrix (GlaxoSmithKline)","volume":"8","author":"Jones","year":"2005","journal-title":"IDrugs"},{"key":"ref101","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2024-066658","article-title":"Haemophilus influenzae Type b Vaccine Immunogenicity in American Indian\/Alaska Native Infants","volume":"154","author":"Jackson","year":"2024","journal-title":"Pediatrics"},{"key":"ref102","doi-asserted-by":"publisher","DOI":"10.1016\/j.canep.2025.102759","article-title":"Investigating factors affecting the effectiveness of Gardasil 4, Cervarix, and Gardasil 9 vaccines considering the WHO regions in females: A systematic review","volume":"95","author":"Zadeh","year":"2025","journal-title":"Cancer Epidemiol"},{"key":"ref103","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.3390\/idr13040094","article-title":"Hepatitis B Vaccination in Advanced Chronic Kidney Disease: A Quality Improvement Project at a Veteran Affairs Chronic Kidney Disease Clinic","volume":"13","author":"Hettenbaugh","year":"2021","journal-title":"Infect Dis Rep"},{"key":"ref104","first-page":"337","article-title":"GSK\u2019s novel split-virus adjuvanted vaccines for the prevention of the H5N1 strain of avian influenza infection","volume":"11","author":"Jones","year":"2009","journal-title":"Curr Opin Mol Ther"},{"key":"ref105","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1007\/s12291-023-01149-w","article-title":"Persistence of SARS-CoV-2 Antibodies for a Year Following SARS-CoV-2 Vaccinations (BBV152 and ChAdOx1 nCoV-19)","volume":"40","author":"Dwivedi","year":"2025","journal-title":"Indian J Clin Biochem"},{"key":"ref106","doi-asserted-by":"publisher","first-page":"7167","DOI":"10.1016\/j.vaccine.2006.06.053","article-title":"A controlled clinical trial comparing the safety and immunogenicity of a new adjuvanted hepatitis B vaccine with a standard hepatitis B vaccine","volume":"24","author":"Dupont","year":"2006","journal-title":"Vaccine"},{"key":"ref107","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines12060635","article-title":"Heterogenous Induction of Blocking Antibodies against Ragweed Allergen Molecules by Allergen Extract-Based Immunotherapy Vaccines","volume":"12","author":"Zb\u00eercea","year":"2024","journal-title":"Vaccines (Basel)"},{"key":"ref108","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2023.2203632","article-title":"Immunogenicity and safety of Biological E's CORBEVAX\u2122 vaccine compared to COVISHIELD\u2122 (ChAdOx1 nCoV-19) vaccine studied in a phase-3, single blind, multicentre, randomized clinical trial","volume":"19","author":"Thuluva","year":"2023","journal-title":"Hum Vaccin Immunother"},{"key":"ref109","doi-asserted-by":"publisher","DOI":"10.1016\/j.pmedr.2025.102981","article-title":"Post-marketing safety surveillance for the recombinant zoster vaccine (Shingrix), vaccine adverse event reporting system, United States, October 2017-April 2024","volume":"50","author":"Shu","year":"2025","journal-title":"Prev Med Rep"},{"key":"ref110","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1007\/s40267-022-00937-3","article-title":"RTS,S\/AS01 malaria vaccine (Mosquirix","volume":"38","author":"Syed","year":"2022","journal-title":"Drugs Ther Perspect"},{"key":"ref111","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2024.126215","article-title":"How has post-implementation surveillance of high-coverage vaccination with HPV16\/18-AS04 vaccine in England added to evidence about its cross-protective effects?","volume":"42","author":"Navarro-Torn\u00e9","year":"2024","journal-title":"Vaccine"},{"key":"ref112","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1016\/j.vaccine.2022.12.009","article-title":"Immunogenicity of the hepatitis B vaccine adjuvanted with AS04C in patients with biological therapies","volume":"41","author":"Mar\u00eda","year":"2023","journal-title":"Vaccine"},{"key":"ref113","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1007\/s42f770-024-01600-x","article-title":"Globally approved vaccines for COVID-19: a systematic review","volume":"56","author":"Magalh\u00e3es","year":"2025","journal-title":"Braz J Microbiol"}],"container-title":["Exploration of Medicine"],"original-title":[],"language":"en","deposited":{"date-parts":[[2025,5,7]],"date-time":"2025-05-07T07:51:37Z","timestamp":1746604297000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.explorationpub.com\/Journals\/em\/Article\/1001316"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,7]]},"references-count":113,"URL":"https:\/\/doi.org\/10.37349\/emed.2025.1001316","archive":["Portico","Portico"],"relation":{},"ISSN":["2692-3106"],"issn-type":[{"value":"2692-3106","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,7]]},"assertion":[{"value":"2024-12-16","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-04-21","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-05-07","order":2,"name":"published","label":"Published Online","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"1001316"}}